Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients

Official Title

A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma


The primary objective of this study was to compare progression-free survival in patients with multiple myeloma who relapsed after 1 to 3 prior therapies treated with carfilzomib plus dexamethasone or bortezomib plus dexamethasone.

Trial Description

Primary Outcome:

  • Progression-free Survival
Secondary Outcome:
  • Overall Survival
  • Overall Response
  • Duration of Response
  • Percentage of Participants With ≥ Grade 2 Peripheral Neuropathy
  • Percentage of Participants With a Significant Reduction in Left Ventricular Ejection Fraction (LVEF)
  • Change From Baseline in Right Ventricular Fractional Area Change (FAC)
  • Change From Baseline in Pulmonary Artery Systolic Pressure (PASP)

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society